Literature DB >> 25803343

Naltrexone extended-release plus bupropion extended-release for treatment of obesity.

Susan Z Yanovski1, Jack A Yanovski2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25803343      PMCID： PMC4993523          DOI： 10.1001/jama.2015.1617

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  7 in total

1.  2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society.

Authors:  Michael D Jensen; Donna H Ryan; Caroline M Apovian; Jamy D Ard; Anthony G Comuzzie; Karen A Donato; Frank B Hu; Van S Hubbard; John M Jakicic; Robert F Kushner; Catherine M Loria; Barbara E Millen; Cathy A Nonas; F Xavier Pi-Sunyer; June Stevens; Victor J Stevens; Thomas A Wadden; Bruce M Wolfe; Susan Z Yanovski
Journal:  J Am Coll Cardiol       Date:  2013-11-12       Impact factor: 24.094

2.  Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Frank L Greenway; Ken Fujioka; Raymond A Plodkowski; Sunder Mudaliar; Maria Guttadauria; Janelle Erickson; Dennis D Kim; Eduardo Dunayevich
Journal:  Lancet       Date:  2010-07-29       Impact factor: 79.321

3.  Meta-analysis: pharmacologic treatment of obesity.

Authors:  Zhaoping Li; Margaret Maglione; Wenli Tu; Walter Mojica; David Arterburn; Lisa R Shugarman; Lara Hilton; Marika Suttorp; Vanessa Solomon; Paul G Shekelle; Sally C Morton
Journal:  Ann Intern Med       Date:  2005-04-05       Impact factor: 25.391

4.  Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.

Authors:  Thomas A Wadden; John P Foreyt; Gary D Foster; James O Hill; Samuel Klein; Patrick M O'Neil; Michael G Perri; F Xavier Pi-Sunyer; Cheryl L Rock; Janelle S Erickson; Holly N Maier; Dennis D Kim; Eduardo Dunayevich
Journal:  Obesity (Silver Spring)       Date:  2010-06-17       Impact factor: 5.002

Review 5.  Long-term drug treatment for obesity: a systematic and clinical review.

Authors:  Susan Z Yanovski; Jack A Yanovski
Journal:  JAMA       Date:  2014-01-01       Impact factor: 56.272

6.  A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).

Authors:  Caroline M Apovian; Louis Aronne; Domenica Rubino; Christopher Still; Holly Wyatt; Colleen Burns; Dennis Kim; Eduardo Dunayevich
Journal:  Obesity (Silver Spring)       Date:  2013-05       Impact factor: 5.002

7.  Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes.

Authors:  Priscilla Hollander; Alok K Gupta; Raymond Plodkowski; Frank Greenway; Harold Bays; Colleen Burns; Preston Klassen; Ken Fujioka
Journal:  Diabetes Care       Date:  2013-10-21       Impact factor: 19.112
  7 in total
  23 in total

Review 1.  Integration of reward signalling and appetite regulating peptide systems in the control of food-cue responses.

Authors:  A C Reichelt; R F Westbrook; M J Morris
Journal:  Br J Pharmacol       Date:  2015-11-01       Impact factor: 8.739

Review 2.  Gastrointestinal traits: individualizing therapy for obesity with drugs and devices.

Authors:  Michael Camilleri; Andres Acosta
Journal:  Gastrointest Endosc       Date:  2015-08-10       Impact factor: 9.427

3.  Putting the brakes on the "drive to eat": Pilot effects of naltrexone and reward-based eating on food cravings among obese women.

Authors:  Ashley E Mason; Barbara Laraia; Jennifer Daubenmier; Frederick M Hecht; Robert H Lustig; Eli Puterman; Nancy Adler; Mary Dallman; Michaela Kiernan; Ashley N Gearhardt; Elissa S Epel
Journal:  Eat Behav       Date:  2015-07-02

4.  Stereoselective Glucuronidation of Bupropion Metabolites In Vitro and In Vivo.

Authors:  Brandon T Gufford; Jessica Bo Li Lu; Ingrid F Metzger; David R Jones; Zeruesenay Desta
Journal:  Drug Metab Dispos       Date:  2016-01-22       Impact factor: 3.922

5.  Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers.

Authors:  Andrea R Masters; Brandon T Gufford; Jessica Bo Li Lu; Ingrid F Metzger; David R Jones; Zeruesenay Desta
Journal:  J Pharmacol Exp Ther       Date:  2016-06-02       Impact factor: 4.030

6.  Progress in Pharmacotherapy for Obesity.

Authors:  Susan Z Yanovski; Jack A Yanovski
Journal:  JAMA       Date:  2021-07-13       Impact factor: 56.272

7.  Pediatric Obesity-Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline.

Authors:  Dennis M Styne; Silva A Arslanian; Ellen L Connor; Ismaa Sadaf Farooqi; M Hassan Murad; Janet H Silverstein; Jack A Yanovski
Journal:  J Clin Endocrinol Metab       Date:  2017-03-01       Impact factor: 5.958

8.  Pharmacotherapy for Weight Management in the VHA.

Authors:  Todd P Semla; Chris Ruser; Chester B Good; Susan Z Yanovski; Donna Ames; Laurel A Copeland; Charles Billington; U Inge Ferguson; Louis J Aronne; Thomas A Wadden; W Timothy Garvey; Caroline M Apovian; David Atkins
Journal:  J Gen Intern Med       Date:  2017-04       Impact factor: 5.128

9.  An open-label trial on the efficacy and tolerability of naltrexone/bupropion SR for treating altered eating behaviours and weight loss in binge eating disorder.

Authors:  Elvira Anna Carbone; Mariarita Caroleo; Marianna Rania; Giuseppina Calabrò; Filippo Antonio Staltari; Renato de Filippis; Matteo Aloi; Francesca Condoleo; Franco Arturi; Cristina Segura-Garcia
Journal:  Eat Weight Disord       Date:  2020-04-30       Impact factor: 4.652

10.  Pharmacological interventions for obesity: current and future targets.

Authors:  Miriam E Bocarsly
Journal:  Curr Addict Rep       Date:  2018-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.